NCT06121765View on ClinicalTrials.gov

Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI

Not yet recruitingOBSERVATIONAL
Enrollment

45

Participants

Timeline

Start Date

November 1, 2023

Primary Completion Date

October 30, 2025

Study Completion Date

November 30, 2025

Conditions
CML, Chronic Phase
Interventions
OTHER

Tyrosine kinase inhibitor

Follow up base metabolic index,lipid profile, HbA1c, thyroid function in CML patients treated with TKI

All Listed Sponsors
lead

Assiut University

OTHER

NCT06121765 - Metabolic Alternation and Clinicohematological Characteristic in Chronic Phase CML in Patient Treated With TKI | Biotech Hunter | Biotech Hunter